175 related articles for article (PubMed ID: 20625122)
21. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
22. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
Gupta V; Yi QL; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
Leuk Res; 2005 Jan; 29(1):113-4. PubMed ID: 15541484
[TBL] [Abstract][Full Text] [Related]
23. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
[TBL] [Abstract][Full Text] [Related]
24. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
Liu YJ; Wu DP; Liang JY; Qiu HY; Jin ZM; Tang XW; Fu CC; Ma X
Med Oncol; 2011 Dec; 28 Suppl 1():S513-21. PubMed ID: 21069477
[TBL] [Abstract][Full Text] [Related]
25. [Effect of additional chromosome abnormalities on the outcome of newly diagnosed acute promyelocytic leukemia treated with red arsenic sulfide and all trans-retinoic acid plus anthracyclin based protocol].
Lu J; Jiang H; Jiang Q; Bao L; Lu XJ; Zhang Y; Lin W; Liu YR; Huang XJ; Jiang B
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2254-7. PubMed ID: 19087672
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
27. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L
J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162
[TBL] [Abstract][Full Text] [Related]
28. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
Martinelli G; Ottaviani E; Testoni N; Visani G; Diverio D; D'Elia G; Mandelli F; Tura S
Haematologica; 1998 Nov; 83(11):985-8. PubMed ID: 9864917
[TBL] [Abstract][Full Text] [Related]
29. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
[TBL] [Abstract][Full Text] [Related]
30. Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?
Park JH; Tallman MS
Expert Rev Hematol; 2011 Aug; 4(4):427-36. PubMed ID: 21801134
[TBL] [Abstract][Full Text] [Related]
31. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
Latagliata R; Breccia M; Fazi P; Vignetti M; Di Raimondo F; Sborgia M; Vincelli D; Candoni A; Salvi F; Rupoli S; Martinelli G; Kropp MG; Tonso A; Venditti A; Melillo L; Cimino G; Petti MC; Avvisati G; Lo-Coco F; Mandelli F;
Br J Haematol; 2011 Sep; 154(5):564-8. PubMed ID: 21751984
[TBL] [Abstract][Full Text] [Related]
32. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Kelaidi C; Ades L; Chevret S; Sanz M; Guerci A; Thomas X; de Botton S; Raffoux E; Rayon C; Fegueux N; Bordessoule D; Rigal-Huguet F; Link H; Stoppa A; Vekhoff A; Meyer-Monard S; Castaigne S; Dombret H; Degos L; Fenaux P
Leukemia; 2006 May; 20(5):905-7. PubMed ID: 16541143
[No Abstract] [Full Text] [Related]
33. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
Sanz MA; Martín G; González M; León A; Rayón C; Rivas C; Colomer D; Amutio E; Capote FJ; Milone GA; De La Serna J; Román J; Barragán E; Bergua J; Escoda L; Parody R; Negri S; Calasanz MJ; Bolufer P;
Blood; 2004 Feb; 103(4):1237-43. PubMed ID: 14576047
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy.
Serefhanoglu S; Buyukasik Y; Goker H; Sayinalp N; Haznedaroglu IC; Aksu S; Ozcebe OI; Turgut M; Aslan R; Ozdemir E
Leuk Res; 2010 Dec; 34(12):e317-9. PubMed ID: 20696473
[No Abstract] [Full Text] [Related]
35. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.
Lobe I; Rigal-Huguet F; Vekhoff A; Desablens B; Bordessoule D; Mounier C; Ferrant A; Sanz M; Fey M; Chomienne C; Chevret S; Degos L; Fenaux P;
Leukemia; 2003 Aug; 17(8):1600-4. PubMed ID: 12886249
[TBL] [Abstract][Full Text] [Related]
36. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
Pollicardo N; O'Brien S; Estey EH; al-Bitar M; Pierce S; Keating M; Kantarjian HM
Leukemia; 1996 Jan; 10(1):27-31. PubMed ID: 8558933
[TBL] [Abstract][Full Text] [Related]
37. Risk-adapted treatment for low- and intermediate-risk acute promyelocytic leukemia.
Sanz MA; Montesinos P
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10 Suppl 3():S130-4. PubMed ID: 21115431
[TBL] [Abstract][Full Text] [Related]
38. [Therapy-related myeloid neoplasms after successful treatment for acute promyelocytic leukemia: a report of four cases and literature review].
Wang Z; Xu MZ; Chen YF; Xue F; Zhang L; Hu YM; Li CW; Li SZ; Wang JX; Mi YC
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1008-1014. PubMed ID: 32023731
[No Abstract] [Full Text] [Related]
39. Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol.
Pellicori P; Calicchia A; Lococo F; Cimino G; Torromeo C
Congest Heart Fail; 2012; 18(4):217-21. PubMed ID: 22809260
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
